Study:
A Phase III Trial Of Modified FOLFOX6 Versus CAPOX, With Bevacizumab (NSC-704865) Or Placebo, As First-Line Therapy In Patients With Previously Untreated Advanced Colorectal Cancer
Rationale:
Drugs used in chemotherapy, such as oxaliplatin, leucovorin, fluorouracil, and
capecitabine, work in different ways to stop cancer cells from dividing so they stop growing
or die. Monoclonal antibodies, such as bevacizumab, can block cancer growth in different
ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells
and help kill them or deliver cancer-killing substances to them. Combining chemotherapy with
monoclonal antibody therapy may kill more tumor cells. It is not yet known which combination
chemotherapy regimen with bevacizumab works better in treating colorectal cancer.
Purpose:
This randomized phase III trial is studying giving two different combination
chemotherapy regimens together with bevacizumab and comparing how well they work in treating
patients with locally advanced, metastatic, or recurrent colorectal cancer.
Study Status: Completed
Recruiting:
n/a
| Condition |
Intervention |
Phase |
|
Colorectal Cancer |
Biological: bevacizumab
Drug: FOLFOX regimen
Drug: capecitabine
Drug: fluorouracil
Drug: leucovorin calcium
Drug: oxaliplatin |
Phase 3 |
Verified by
Southwest Oncology Group
August, 2004
Sponsored by: Southwest Oncology Group
Information provided by: National Cancer Institute (NCI)
ClinicalTrials.gov identifier: NCT00070122
Study Type: Interventional
Study Design: Allocation: Randomized, Control: Active Control, Primary Purpose: Treatment
Cleveland Clinic Taussig Cancer Center
Cleveland, Ohio 44195-9001
United States
Charles D. Blanke, MD, FACP.,
Heinz-Josef Lenz, MD.,